SCHEMBL2652422

SCHEMBL2652422

FC(F)Oc1cccc(-c2ncc[nH]2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 2/20 0.50
MTOR P42345 1/20 0.50
ADK P55263 1/20 0.50
DRD1 P21728 1/20 0.46
MAP4K4 O95819 1/20 0.45
KCNH2 Q12809 1/20 0.42
MRGPRX4 Q96LA9 1/20 0.41
VCP P55072 2/20 0.41
PRMT5 O14744 1/20 0.40
WDR77 Q9BQA1 1/20 0.40
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
GRM4 Q14833 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP19A1 P11511 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
GRIN1 Q05586 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1288383 0.82 NPY5R (0.52) NISCHMTORADKKCNH2MRGPRX4
SCHEMBL2651783 0.81 CYP1A2 (0.55) NISCHMTORADKDRD1KCNH2
Iodide SCHEMBL27779883 0.81 NPY5R (0.51) NISCHMTORADKKCNH2MRGPRX4
SCHEMBL10276854 0.80 NISCH (0.51) NISCHMTORADKKCNH2MRGPRX4
SCHEMBL2097610 0.80 DYRK1A (0.57) NISCHMTORADKALDH1A1KDM4E
SCHEMBL2097606 0.80 NISCH (0.55) NISCHMTORADKKCNH2MRGPRX4
SCHEMBL6002994 0.79 NISCH (0.47) NISCHMTORADKKCNH2MRGPRX4
SCHEMBL6002386 0.79 NISCH (0.50) NISCHMTORADKKCNH2MRGPRX4
SCHEMBL16777437 0.78 NISCH (0.72) NISCHMTORADKMRGPRX4VCP
SCHEMBL27311078 0.77 NISCH (0.51) NISCHMTORADKMAP4K4VCP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104334557-A Diacylglycerol acyltransferase 2 inhibitors PFIZER 2015-02-04 CN disclosed
EP-1635813-A4 COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA MERCK & CO INC (US) 2009-07-01 EP disclosed
EP-1534074-A4 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY MERCK & CO INC (US) 2008-01-09 EP disclosed
EP-1799241-A2 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY Merck & Co., Inc. (US) 2007-06-27 EP disclosed
WO-2006036770-A2 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY MERCK & CO., INC. (US) 2006-04-06 WO disclosed
EP-1635832-A2 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES Merck & Co., Inc. (US) 2006-03-22 EP disclosed
EP-1635813-A2 COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA Merck & Co. Inc. (US) 2006-03-22 EP disclosed
EP-1635773-A2 COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION Merck & Co., Inc. (a New Jersey corp.) (US) 2006-03-22 EP disclosed
EP-1534074-A2 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY Merck & Co., Inc. (US) 2005-06-01 EP disclosed
WO-2005000217-A2 COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA MERCK & CO., INC. (US) 2005-01-06 WO disclosed
WO-2004110375-A2 COMBINATION THERAPY FOR THE TREATMENT OF DIABETES MERCK & CO., INC. (US) 2004-12-23 WO disclosed
WO-2004110368-A2 COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION MERCK & CO., INC. (US) 2004-12-23 WO disclosed
WO-2004009015-A2 COMBINATION THERAPY FOR THE TREATMENT OF OBESITY MERCK & CO., INC. (US) 2004-01-29 WO disclosed